| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/27/2002 | EP1191025A1 Crystals of benzimidazole compounds |
| 03/27/2002 | EP1191019A1 Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof |
| 03/27/2002 | EP1190726A2 Liquefied embolic materials capable of sol-gel phase transition and their use |
| 03/27/2002 | EP1190721A2 A method for the anhydrous loading of nicotine onto ion exchange resins |
| 03/27/2002 | EP1190720A1 Liquid pharmaceutical composition for oral administration of bitter hydrolysis-susceptible active substances |
| 03/27/2002 | EP1190715A1 Bactericide against vancomycin resistant enterococcus |
| 03/27/2002 | EP1190714A2 Method for the treatment of thromboembolic disorders in patients with aspirin resistance |
| 03/27/2002 | EP1190713A1 Advanced glycation end-product intermediaries and post-amadori inhibition |
| 03/27/2002 | EP1190712A1 Oral once daily tramadol beads composition |
| 03/27/2002 | EP1190711A1 Treatment of diseases with adamantane derivatives |
| 03/27/2002 | EP1190710A1 Preventive or therapeutic drugs for diabetes |
| 03/27/2002 | EP1190709A1 Treatment of tinnitus |
| 03/27/2002 | EP1190708A1 Medical use of substances |
| 03/27/2002 | EP1190705A1 Method of regulating leakage of drug encapsulated in liposomes |
| 03/27/2002 | EP1190703A1 Composition comprising glycoglycerides and their cosmetic use |
| 03/27/2002 | EP1190630A1 Use of prenylated flavones |
| 03/27/2002 | EP1190629A1 Omega-3 fatty acids in combination with a concentrated vitamin E source |
| 03/27/2002 | EP1190255A1 Epitopes formed by non-covalent association of conjugates |
| 03/27/2002 | EP1190249A2 Compounds and methods to enhance raav transduction |
| 03/27/2002 | EP1190248A1 Screening methods for compounds which affect melanogenesis |
| 03/27/2002 | EP1190099A1 Antisense modulation of pi3k p85 expression |
| 03/27/2002 | EP1190086A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 03/27/2002 | EP1190079A2 Control of gene expression in eukaryotic cells |
| 03/27/2002 | EP1190077A2 Genetic sequence which codes for the flavon synthase ii enzyme and use of the same |
| 03/27/2002 | EP1190065A2 Atp binding cassette transporter protein abc1 polypeptides |
| 03/27/2002 | EP1190063A1 Nucleic and proteinic acids corresponding to human gene abc1 |
| 03/27/2002 | EP1190059A1 Sgip peptides |
| 03/27/2002 | EP1190057A1 Cloning and expression of a novel 5-ht4 receptor |
| 03/27/2002 | EP1190053A2 Mammalian calcium channels and related probes, cell lines and methods |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1190049A1 Spliceosome protein and its use |
| 03/27/2002 | EP1190047A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 03/27/2002 | EP1189926A2 Rapid dehydration of proteins |
| 03/27/2002 | EP1189924A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 03/27/2002 | EP1189923A1 Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease |
| 03/27/2002 | EP1189922A1 Steroid derivatives |
| 03/27/2002 | EP1189917A1 48 human secreted proteins |
| 03/27/2002 | EP1189916A2 N-pyrazole a 2a receptor agonists |
| 03/27/2002 | EP1189915A1 Process for the production of azithromycin |
| 03/27/2002 | EP1189914A1 DERIVATIVES OF 4'-DEMYCAROSYL-8a-AZA-8a-HOMOTYLOSIN |
| 03/27/2002 | EP1189913A1 Diphosphate salt of a 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition |
| 03/27/2002 | EP1189912A1 Novel crystalline forms of a macrolide antibiotic |
| 03/27/2002 | EP1189908A1 Indolocarbazole alkaloids from a marine actinomycete |
| 03/27/2002 | EP1189907A1 Thienopyrimidines as phosphodiesterase inhibitors |
| 03/27/2002 | EP1189905A1 Substituted heterocycle fused gamma-carbolines |
| 03/27/2002 | EP1189904A1 Substituted heterocycle fused gamma-carbolines |
| 03/27/2002 | EP1189903A1 Novel benzo f]naphthyridine, preparation and compositions containing them |
| 03/27/2002 | EP1189900A1 Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| 03/27/2002 | EP1189899A1 Pyrazinone thrombin inhibitors |
| 03/27/2002 | EP1189897A1 Isoflavone metabolites |
| 03/27/2002 | EP1189896A1 Substituted 5-oxo-5,6,7,8-tetrahydro-4h-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of ampa |
| 03/27/2002 | EP1189895A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 03/27/2002 | EP1189894A1 Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer |
| 03/27/2002 | EP1189892A1 Melamine derivatives as potent anti-cancer agents |
| 03/27/2002 | EP1189891A1 Triazole compounds and combinatorial libraries thereof |
| 03/27/2002 | EP1189890A1 Dihydrobenzodiazepins and their use for treating dyslipidemia |
| 03/27/2002 | EP1189889A1 Compositions and methods for inhibiting cell death |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189887A2 Process for preparing 10,11-methanobenzosuberane derivatives |
| 03/27/2002 | EP1189886A1 Ethanesulfonyl-piperidine derivatives |
| 03/27/2002 | EP1189883A2 Substituted pyrrolidines as cell adhesion inhibitors |
| 03/27/2002 | EP1189882A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor |
| 03/27/2002 | EP1189881A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 03/27/2002 | EP1189879A1 INHIBITORS OF FACTOR Xa |
| 03/27/2002 | EP1189874A1 Excitatory amino acid receptor modulators |
| 03/27/2002 | EP1189873A1 Excitatory amino acid receptor modulators |
| 03/27/2002 | EP1189862A1 Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates |
| 03/27/2002 | EP1189749A1 Composite laminate and method for its production |
| 03/27/2002 | EP1189663A2 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 03/27/2002 | EP1189662A1 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
| 03/27/2002 | EP1189641A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/27/2002 | EP1189640A1 Pharmaceutical complex |
| 03/27/2002 | EP1189638A2 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 03/27/2002 | EP1189637A2 Compositions for improving bioavailability of orally administered drugs |
| 03/27/2002 | EP1189634A1 Treating prostate cancer with anti-erbb2 antibodies |
| 03/27/2002 | EP1189633A2 Method for treating chronic hbv infection |
| 03/27/2002 | EP1189631A1 Neurodegenerative disorder related gene |
| 03/27/2002 | EP1189628A1 Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 03/27/2002 | EP1189626A1 Method for preventing tumoral growth |
| 03/27/2002 | EP1189625A1 Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
| 03/27/2002 | EP1189622A2 Anionic polymers as toxin binders and antibacterial agents |
| 03/27/2002 | EP1189621A1 Unfermented gel fraction from psyllium seed husks |
| 03/27/2002 | EP1189620A1 Formulation comprising testosteron undecanoate and castor oil |
| 03/27/2002 | EP1189619A1 Administration of non-oral androgenic steroids to women |
| 03/27/2002 | EP1189618A1 Thrombin inhibitors |
| 03/27/2002 | EP1189617A1 Novel pharmaceutical combination with analgesic action containing paracetamol and buspirone |
| 03/27/2002 | EP1189616A2 S-hydroxynefazodone |
| 03/27/2002 | EP1189615A2 Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines |
| 03/27/2002 | EP1189614A2 Solid preparations containing paroxetine |
| 03/27/2002 | EP1189613A1 Method for the treatment of neurological or neuropsychiatric disorders |
| 03/27/2002 | EP1189612A1 Vla-4 inhibitor compounds |
| 03/27/2002 | EP1189611A1 Cancer therapy |
| 03/27/2002 | EP1189610A1 Method and markers for prognosticating efficacy of anticancer agents |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189608A1 Levodopa/carbidopa/entacapone pharmaceutical preparation |
| 03/27/2002 | EP1189607A2 Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives |
| 03/27/2002 | EP1189606A2 Novel iron chelators and pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders |
| 03/27/2002 | EP1189605A2 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 03/27/2002 | EP1189604A2 Zinc ionophores as anti-apoptotic agents |
| 03/27/2002 | EP1189603A2 Treatment of immune diseases like hiv disease and neoplastic disorders |